Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gastric Bypass In A Pill: New Angles On Diabetes Drug Development

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Emerging targets are looking at diabetes/obesity crossover, as well as immunometabolic approaches that overlap with dyslipidemia.

You may also be interested in...

Partnering Opportunities In Cardio/Metabolics: “Everybody’s Looking And Nobody’s Got”

Representatives from J&J, GSK, Pfizer and Boehringer Ingelheim discuss their companies’ thinking in terms of cardiovascular/metabolic drug development and business development activity at the TAP conference.

Obesity And Diabetes: Toward A Surgical Solution: An Interview With Francesco Rubino, MD

A new position statement from the International Diabetes Federation that endorses bariatric surgery as a medically indicated therapeutic option for diabetes represents an important philosophical shift for this field, according to Francesco Rubino, MD, chief of gastrointestinal metabolic surgery at Weill Cornell Medical College.

Dapagliflozin’s CV Profile Shines, But FDA Panel Review Falls On Cancer Concerns

The July 19 FDA advisory committee meeting on Bristol-Myers Squibb Co./AstraZeneca PLC's dapagliflozin reflects the hurdles facing type 2 diabetes drug sponsors even when cardiovascular safety concerns are taken out of the picture.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts